Investor Relations

INVESTOR RELATIONSCORPORATE MILESTONES

Corporate Milestones

Year	Milestones
2011	European patent granted for G1A™ Test Epinex enters into exclusive licensing and marketing agreement with S. Korea Epinex Diagnostics Laboratories, Inc. passes state license inspection and begins patient testing Epinex registers patent for G1A™ test in Hong Kong Third Private Placement launched for $5 million Epinex welcomes Dr. Alan Carter to Scientific Advisory Board Epinex chosen to present at: Kentucky's annual statewide diabetes symposium, Diabetes Technology Society's 7th annual Clinical Diabetes Technology Meeting Epinex develops diabetes track for Q1 Production's 3rd annual Partnerships in Personalized Medicine Conference
2010	Epinex receives federal QTDP grant USPTO grants Epinex its main technology patent Construction of laboratory and manufacturing spaces finalized Epinex expands to larger facility in Tustin, CA
2009	Frost & Sullivan Award for Global Excellence in Diabetes Research 3rd generation handheld prototype completed Epinex CEO Asad Zaidi presented with SABAN award for entrepreneurial success Epinex prepares detailed marketing and media plan for the G1A™ test Epinex invited to New York Academy of Sciences conference on diabetes
2008	Second Private Placement launched for $15 million Corporate Information Series published: Understanding Diabetes Glycated Albumin and Diabetes Monitoring Diabetes in The Middle East Review article published in the peer-reviewed diabetes research journal The Journal of Diabetes of Science and Technology Peptide and custom antibody projects initiated to produce proprietary analytes for the G1A™ test Desktop/doctor's office reader prototype and software design completed
2007	Oakridge Poster Presentation of posters at major clinical chemistry meetings: AACC Oakridge Conference in Oakland, CA, 2007 Annual AACC Meeting in San Diego, CA and IFCC EuroMedlab Conference in Amsterdam, The Netherlands First Action taken on US and European patent applications First Private Placement Memorandum offering for $5 million successfully completed
2006	G1A™ Test Strip Prototype: Initial prototype single channel test strips for total and glycated albumin designed and tested US and European patent applications published Glycated Albumin abstract and review published G1A™ Handheld Prototype: Single channel handheld reader completed 2nd Open House and live webcast for investors held
2005	WIPO application published G1A™ test feasibility survey sent to 3500 endocrinologist worldwide 1st Open House: Hosted an open house for Company investors and local business contacts Monograph published: "Towards a New Glycation Index", background information about glycemic control and glycated albumin GA Test signal amplified
2004	Advisory Board assembled European, Canadian, Japanese provisional patents filed
2003	First Private Placement Memorandum launched for $5 million Preliminary background research on the Glycated Albumin molecule was conducted to evaluate feasibility Provisional US patent filed
2002	Epinex Diagnostics incorporated as California C-corp

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the news section and the most recent SEC Fillings in the Investor section in order receive the most current information made available by Epinex Diagnostics, Inc. Contact Us with any questions or search this site for more information.